PT3078372T - Agente terapêutico para doenças que têm por base o efeito inibidor do fator inibidor da migração de macrófagos - Google Patents

Agente terapêutico para doenças que têm por base o efeito inibidor do fator inibidor da migração de macrófagos

Info

Publication number
PT3078372T
PT3078372T PT161694146T PT16169414T PT3078372T PT 3078372 T PT3078372 T PT 3078372T PT 161694146 T PT161694146 T PT 161694146T PT 16169414 T PT16169414 T PT 16169414T PT 3078372 T PT3078372 T PT 3078372T
Authority
PT
Portugal
Prior art keywords
inhibitor
therapeutic agent
macrophage migration
diseases based
factor
Prior art date
Application number
PT161694146T
Other languages
English (en)
Inventor
Tanaka Keiichi
Morimoto Kimiko
Original Assignee
Toyama Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyama Chemical Co Ltd filed Critical Toyama Chemical Co Ltd
Publication of PT3078372T publication Critical patent/PT3078372T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/24Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT161694146T 2013-07-18 2014-07-17 Agente terapêutico para doenças que têm por base o efeito inibidor do fator inibidor da migração de macrófagos PT3078372T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013149690 2013-07-18

Publications (1)

Publication Number Publication Date
PT3078372T true PT3078372T (pt) 2017-10-18

Family

ID=52346269

Family Applications (2)

Application Number Title Priority Date Filing Date
PT161694146T PT3078372T (pt) 2013-07-18 2014-07-17 Agente terapêutico para doenças que têm por base o efeito inibidor do fator inibidor da migração de macrófagos
PT148268113T PT2929880T (pt) 2013-07-18 2014-07-17 Agente terapêutico para doenças que têm por base o efeito inibidor do fator inibidor da migração de macrófagos

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT148268113T PT2929880T (pt) 2013-07-18 2014-07-17 Agente terapêutico para doenças que têm por base o efeito inibidor do fator inibidor da migração de macrófagos

Country Status (22)

Country Link
US (3) US20150353519A1 (pt)
EP (2) EP3078372B1 (pt)
JP (2) JP5802868B2 (pt)
CN (1) CN105407887B (pt)
AU (1) AU2014291149B2 (pt)
CA (1) CA2918325C (pt)
CY (2) CY1118140T1 (pt)
DK (2) DK2929880T3 (pt)
ES (2) ES2642440T3 (pt)
HR (2) HRP20161317T1 (pt)
HU (2) HUE029800T2 (pt)
IL (1) IL243550B (pt)
LT (2) LT2929880T (pt)
NO (1) NO3078372T3 (pt)
PL (2) PL2929880T3 (pt)
PT (2) PT3078372T (pt)
RS (2) RS56489B1 (pt)
RU (2) RU2750540C2 (pt)
SI (2) SI3078372T1 (pt)
SM (3) SMT201700080T1 (pt)
TW (1) TWI603965B (pt)
WO (1) WO2015008827A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6901571B2 (ja) * 2017-01-26 2021-07-14 四川瀛瑞医薬科技有限公司Sichuan Yingrui Pharmaceutical Technology Company ナノ炭素−鉄複合システム及びその組成物、調製方法並びに使用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0753725B2 (ja) 1987-10-08 1995-06-07 富山化学工業株式会社 4h―1―ベンゾピラン―4―オン誘導体およびその塩、それらの製造法並びにそれらを含有する抗炎症剤
EP0695547B1 (en) 1993-04-09 2001-08-08 Toyama Chemical Co., Ltd. Immunomodulator, cell adhesion inhibitor, and agent for treating and preventing autoimmune diseases
EP0868598B1 (de) * 1995-12-21 1999-10-27 Siemens Aktiengesellschaft Luftansaugvorrichtung mit variabler saugrohrlänge für eine brennkraftmaschine
DE10044091A1 (de) * 2000-09-07 2002-04-04 Merck Patent Gmbh Chromanonderivate
GB0507695D0 (en) 2005-04-15 2005-05-25 Novartis Ag Organic compounds
GB0507696D0 (en) * 2005-04-15 2005-05-25 Novartis Ag Organic compounds
EP1940382A2 (en) * 2005-10-07 2008-07-09 Aditech Pharma AB Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
RU2611341C2 (ru) 2011-08-30 2017-02-21 Тояма Кемикал Ко., Лтд. Способ увеличения эффективности терапии аутоиммунных заболеваний, таких как ревматоидный артрит

Also Published As

Publication number Publication date
PL3078372T3 (pl) 2018-02-28
DK2929880T3 (da) 2017-01-02
RS56489B1 (sr) 2018-01-31
EP3078372B1 (en) 2017-09-13
SMT201700080T1 (it) 2017-03-08
US20160228406A1 (en) 2016-08-11
CN105407887A (zh) 2016-03-16
EP2929880B1 (en) 2016-09-14
US20160228404A1 (en) 2016-08-11
RS55394B1 (sr) 2017-04-28
LT2929880T (lt) 2016-11-25
CY1119496T1 (el) 2018-03-07
WO2015008827A1 (ja) 2015-01-22
SI2929880T1 (sl) 2016-12-30
TWI603965B (zh) 2017-11-01
EP2929880A4 (en) 2015-10-14
NO3078372T3 (pt) 2018-02-10
IL243550A0 (en) 2016-02-29
EP2929880A1 (en) 2015-10-14
SMT201700080B (it) 2017-03-08
ES2642440T3 (es) 2017-11-16
ES2593527T3 (es) 2016-12-09
EP3078372A1 (en) 2016-10-12
SMT201700606T1 (it) 2018-01-11
CA2918325A1 (en) 2015-01-22
AU2014291149B2 (en) 2017-05-04
RU2641301C2 (ru) 2018-01-17
RU2016105141A (ru) 2017-08-23
HUE029800T2 (en) 2017-04-28
RU2017131951A (ru) 2019-02-06
JP2016034953A (ja) 2016-03-17
PL2929880T3 (pl) 2017-03-31
JP6060231B2 (ja) 2017-01-11
LT3078372T (lt) 2017-11-27
PT2929880T (pt) 2016-11-08
US20150353519A1 (en) 2015-12-10
AU2014291149A1 (en) 2016-02-11
HK1222556A1 (zh) 2017-07-07
RU2017131951A3 (pt) 2020-12-18
HUE034661T2 (en) 2018-02-28
JP5802868B2 (ja) 2015-11-04
HRP20161317T1 (hr) 2016-12-16
TW201536764A (zh) 2015-10-01
CA2918325C (en) 2018-06-26
DK3078372T3 (en) 2017-10-16
SI3078372T1 (en) 2018-01-31
CN105407887B (zh) 2018-09-04
CY1118140T1 (el) 2017-06-28
RU2750540C2 (ru) 2021-06-29
JPWO2015008827A1 (ja) 2017-03-02
IL243550B (en) 2019-06-30
HRP20171497T1 (hr) 2017-11-17
US9918963B2 (en) 2018-03-20

Similar Documents

Publication Publication Date Title
IL283943A (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k related disorders
CY2025015I1 (el) Χρηση του αναστολεα τελομερασης ιμετελστατη για τη θεραπευτικη αγωγη του μυελοδυσπλαστικου συνδρομου
BR112016000489A2 (pt) composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos
DK3289080T3 (da) Genterapi til autosomalt dominante sygdomme
EP3391284A4 (en) EVALUATION AND QUANTIFICATION OF EMERGENCY FUNCTIONS ON A HEAD COMPUTER TOMOGRAPHY
PL3012327T3 (pl) Sposób przewidywania skuteczności terapeutycznej inhibitora PI3K/AKT/mTOR na podstawie ekspresji PHLDA1 lub PIK3C2B
PT2976360T (pt) Terapia envolvendo anticorpos contra claudina 18.2 para o tratamento de cancro
PT3116547T (pt) Nanopartículas terapêuticas que compreendem um agente terapêutico e métodos para produzir e utilizar as mesmas
EP3736015C0 (en) Multi-unit drug delivery devices
PT2872497T (pt) Derivados de cromanilo para o tratamento de doenças mitocondriais
BR112016008886A2 (pt) Elemento de suporte para o corpo humano
HUE042763T2 (hu) Módosított szerpinek vérzési rendellenességek kezelésére
PL3381451T3 (pl) Kompozycja farmaceutyczna stosowana do redukcji zlokalizowanej tkanki tłuszczowej i zastosowanie kompozycji farmaceutycznej
PT2859896T (pt) Composições farmacêuticas para o tratamento de distúrbios musculares
IL268728A (en) Formulations of cannabinoids for the treatment of acne
PT3592355T (pt) Kx2-391/kx-01 para utilização no tratamento da queratose actínica
IL242220A0 (en) Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
PT3360547T (pt) Composição farmacêutica bactericida que compreende ibuprofeno
CL2015003585A1 (es) Combinaciones para el tratamiento de cáncer que comprende un inhibidor de la quinasa mps-1 y un inhibidor de la mitosis
EP2987489A4 (en) MEDICINAL FORMULATION WITH DELAYED RELEASE
BR112015010428A2 (pt) agente terapêutico para distúrbios ceratoconjuntivos
EP2949329A4 (en) THERAPEUTIC AGAINST DEMYELINISING DISEASE
PT2929880T (pt) Agente terapêutico para doenças que têm por base o efeito inibidor do fator inibidor da migração de macrófagos
BR112017000539A2 (pt) agente terapêutico para distúrbio ceratoconjuntivo
PT2956129T (pt) Composições farmacêuticas que contêm dexcetoprofeno e tramadol